Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer.

Literature DB >> 18640945

Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer.

Vincenzo Pitini¹, Carmela Arrigo, Giuseppe Altavilla.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2008 PMID： 18640945 DOI： 10.1200/JCO.2008.17.0357

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

Keyword Cloud
Cited

× No keyword cloud information.

13 in total

Review 1. The secret ally: immunostimulation by anticancer drugs.

Authors: Lorenzo Galluzzi; Laura Senovilla; Laurence Zitvogel; Guido Kroemer
Journal: Nat Rev Drug Discov Date: 2012-02-03 Impact factor: 84.694

2. Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.

Authors: Rami S Komrokji; Eric Padron; Daohai Yu; William J Fulp; Yuraima Rodriguez; Sara Tinsley; Alan F List; Jeffrey E Lancet
Journal: Am J Hematol Date: 2014-05-16 Impact factor: 10.047

Review 3. Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.

Authors: Anna E Kersh; Spencer Ng; Yun Min Chang; Maiko Sasaki; Susan N Thomas; Haydn T Kissick; Gregory B Lesinski; Ragini R Kudchadkar; Edmund K Waller; Brian P Pollack
Journal: J Clin Pharmacol Date: 2017-11-14 Impact factor: 3.126

4. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia.

Authors: Daniel J Deangelo; Donna Neuberg; Philip C Amrein; Jacob Berchuck; Martha Wadleigh; L Andres Sirulnik; Ilene Galinsky; Todd Golub; Kimberly Stegmaier; Richard M Stone
Journal: Leuk Res Date: 2013-11-05 Impact factor: 3.156

5. Erlotinib antagonizes ABC transporters in acute myeloid leukemia.

Authors: Elodie Lainey; Marie Sébert; Sylvain Thépot; Marie Scoazec; Cyrielle Bouteloup; Carole Leroy; Stéphane De Botton; Lorenzo Galluzzi; Pierre Fenaux; Guido Kroemer
Journal: Cell Cycle Date: 2012-10-24 Impact factor: 4.534

6. Proteomic and genetic approaches identify Syk as an AML target.

Authors: Cynthia K Hahn; Jacob E Berchuck; Kenneth N Ross; Rose M Kakoza; Karl Clauser; Anna C Schinzel; Linda Ross; Ilene Galinsky; Tina N Davis; Serena J Silver; David E Root; Richard M Stone; Daniel J DeAngelo; Martin Carroll; William C Hahn; Steven A Carr; Todd R Golub; Andrew L Kung; Kimberly Stegmaier
Journal: Cancer Cell Date: 2009-10-06 Impact factor: 31.743

7. EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic acid and vitamin D3 in acute myeloid leukemia cells.

Authors: Elodie Lainey; Alice Wolfromm; Abdul Qader Sukkurwala; Jean-Baptiste Micol; Pierre Fenaux; Lorenzo Galluzzi; Oliver Kepp; Guido Kroemer
Journal: Cell Cycle Date: 2013-08-13 Impact factor: 4.534